BioSpace News Archive

Collegium Pharmaceutical, Inc., a leading, diversified specialty pharmaceutical company, announced that management will participate in the following investor conference.

Inventiva announced that the abstract “Lanifibranor, a pan-PPAR agonist, improves markers of cardiometabolic health in patients with NASH” has been selected for oral presentation during the third International Conference on Fatty Liver to be held from the 28th to the 30th of April 2022 in Vienna, Austria.

CRISPR Therapeutics, a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announced that members of its senior management team are scheduled to participate in the following investor conferences in April.

Global Blood Therapeutics, Inc. announced that on April 1, 2022, the compensation committee of GBT’s board of directors granted 21 new employees restricted stock units for an aggregate of 64,050 shares of the company’s common stock.

Curis, Inc. announced that on April 1, 2022, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 380,850 shares of Curis common stock to seven new employees, with a grant date of April 1, 2022.

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company developing novel T cell engagers, announced that Natalie Sacks, M.D., Chief Medical Officer, will be leaving the company effective June 1, 2022.

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today announced that Chief Financial Officer John Sharp will participate in a fireside chat at the 21st Annual Needham Healthcare Conference.

A vascular graft is a surgical procedure that reconnects blood vessels and redirects blood flow from one part of the body to another. They are widely used for the surgery of vascular diseases.

GABA Therapeutics, Inc, a clinical-stage biotechnology company developing novel therapies for anxiety, depression and other neurological disorders, and part of the atai Life Sciences platform, announces the appointment of Mario David Saltarelli M.D., Ph.D. as Chief Executive Officer and Chief Medical Officer effective April 4, 2022.

Genmab A/S (Nasdaq: GMAB) announced today an award in the binding arbitration of two matters arising under its license agreement with Janssen Biotech, Inc. (Janssen) relating to daratumumab.